Efficacy, safety, and mitochondrial mechanisms of myricetin in a preclinical model of trastuzumab-resistant HER2(+) breast cancer.
- DOI
- 10.1016/j.tiv.2026.106294
- Published
- 2026 Dec
- Container
- Toxicology in vitro : an international journal published in association with BIBRA
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.tiv.2026.106294,
title = {Efficacy, safety, and mitochondrial mechanisms of myricetin in a preclinical model of trastuzumab-resistant HER2(+) breast cancer.},
author = {Zhu Y and Yang W and Guan G and Zhou C},
year = {2026},
journal = {Toxicology in vitro : an international journal published in association with BIBRA},
doi = {10.1016/j.tiv.2026.106294},
url = {https://doi.org/10.1016/j.tiv.2026.106294}
}RIS
TY - JOUR TI - Efficacy, safety, and mitochondrial mechanisms of myricetin in a preclinical model of trastuzumab-resistant HER2(+) breast cancer. AU - Zhu Y AU - Yang W AU - Guan G AU - Zhou C PY - 2026 JO - Toxicology in vitro : an international journal published in association with BIBRA DO - 10.1016/j.tiv.2026.106294 UR - https://doi.org/10.1016/j.tiv.2026.106294 ER -
APA
Y, Z., W, Y., G, G., & C, Z. (2026). Efficacy, safety, and mitochondrial mechanisms of myricetin in a preclinical model of trastuzumab-resistant HER2(+) breast cancer.. Toxicology in vitro : an international journal published in association with BIBRA. https://doi.org/10.1016/j.tiv.2026.106294
Source records
- pubmed · retrieved 2026-09-25T20:27:05.802Z
- europe-pmc · retrieved 2026-09-25T20:27:05.827Z